The problem to be solved by this invention is to provide a composition for inhibiting nerve cell injury caused by Aβ. This problem is solved by a composition for inhibiting nerve cell injury caused by Aβ, comprising a Kampo extract that contains a glycyrrhiza extract.

The problem to be solved by this invention is to provide a composition for inhibiting nerve cell injury caused by Aβ. This problem is solved by a composition for inhibiting nerve cell injury caused by Aβ, comprising a Kampo extract that contains a glycyrrhiza extract.

Pharmaceutical compositions containing a combination of rhizoma coptidis and a herbal composition comprises at least one herb selected from the group consisting of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae and Radix Glycyrrhizae are disclosed. Methods of treating diseases by administering an effective amount of the pharmaceutical composition are also provided.

Pharmaceutical compositions containing a combination of rhizoma coptidis and a herbal composition comprises at least one herb selected from the group consisting of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae and Radix Glycyrrhizae are disclosed. Methods of treating diseases by administering an effective amount of the pharmaceutical composition are also provided.

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

An embodiment of the present invention provides an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, including: an ephedra powder agent of which ephedrine content is concentrated to be 3.0 to 4.0%, which is greater than 0.5 to 2.5% when it is in a natural state, and of which the ephedrine content is maintained constant at 3.0 to 4.0%; and a side-effect-preventing powder agent for each constitution prescribed based on Sasang constitutional medicine in order to prevent a side effect of the ephedra powder agent, wherein a weight ratio of the ephedra powder agent and the side-effect-preventing powder agent is 8-10:1 to 9-11:1.

Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.

Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.

Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.